RE:RE:RE:RE:RE:Another New Job Posting: Paralegal, Corporate & Securities I don't know but I’m guesstimating first negotiations with Consonance began in Q1 2019 and their exit, Q3, 2020, so not such a shot time, 18 - 24 months. More than enough time to reconsider marketing Ryplazim.
II also don’t believe that Consonance sold at a loss. There were two spikes with high volume in 2020, July 1st ($31) and July 30 ($25). This could have been their exit(s) point(s) with a decent profit as both days were manipulated without a doubt.
Lastly, this is just my opinion and how I see it. Just trying to make sense of it all. And no, I don’t believe this is all part of a master-plan to screw over the retail investors and take the remaining 15% or so that we own. Draw your own conclusions.
hankman wrote: You posted: "hey figured that the return on Ryplazim was not worth the extra 10’s of millions (??) to bring it to market. This could also explain why Consonance jumped ship."
So what happened in the short time from when they convinced Consonance to invest in the recapitalization until the short while later when Consonance sold out at a loss? Did that much change over that short time? They were in full control and in the drivers seat. SO WHAT WENT WRONG??